JAMA: Evaluation of the efficacy of intravenous Eptinezumab during migraine attacks

The clinical manifestations of migraine are repeated episodes of moderate to severe headaches.
Without treatment intervention, the symptoms usually last for several hours to several days, accompanied by nausea and sensory disturbances
.

Recent studies have shown that 34.

FDA Prevention Researchers recently evaluated the efficacy and safety of Eptinezumab during migraine attacks

This study is a phase III, multi-center, parallel group, double-blind, randomized placebo-controlled trial, carried out in 47 centers in the United States, recruiting participants with a history of migraine for more than one year.
The patients are 18-75 years old.
During the 3 months before the screening , migraine attacks occurred for 4 to 15 days per month
.

Patients were randomized to receive 100 mg Eptinezumab (n=238) or placebo (n=242), and the treatment was completed within 1 to 6 hours after the onset of migraine

Screening

The average age of the patients was 44 years, 84% were women, and 476 people completed the study
.

Compared with placebo, Eptinezumab treatment significantly accelerated headache relief (average relief time: 4 hours vs.

Compared with placebo, Eptinezumab treatment significantly accelerated headache relief (average relief time: 4 hours vs.

No differences in headache and irritability symptoms between groups

Studies believe that for patients with moderate to severe migraine attacks, intravenous injection of Eptinezumab can shorten the headache time and accelerate the resolution of irritable symptoms

For patients with moderate to severe migraine attacks, intravenous injection of Eptinezumab can shorten the headache time and accelerate the resolution of irritable symptoms.

Original source:

Paul K.

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack A Randomized Clinical Trial.
JAMA Leave a message here